

References

1. Charcot JM. Lectures on the Diseases of the Nervous System. New Sydenham Society, 1877.
2. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. *Neurology*. 1991;41(5):685-691.
3. Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. *Mult Scler*. 2017;23(5):721-733.
4. Benedict RH, Amato MP, DeLuca J, Geurts JJ. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. *Lancet Neurol*. 2020;19(10):860-871.
5. Rudick RA, LaRocca NG, Hudson LD, et al. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan. *Mult Scler*. 2014;20(1):12-17.
6. LaRocca NG, Hudson LD, Rudick R, et al. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. *Mult Scler*. 2018;24(11):1469-1484.
7. Strober L, DeLuca J, Benedict RH, et al. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. *Mult Scler*. 2019;25(13):1781-1790.
8. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. *Mult Scler*. 2010;16(2):228-237.
9. Edgar C, Jongen PJ, Sanders E, et al. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. *BMC Neurol*. 2011;11:68.
10. Wojcik CM, Beier M, Costello K, et al. Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review. *Mult Scler*. 2019;25(14):1848-1869.
11. Dondé C, Massot C, Maltête D, Guillevin R, Vermersch P. Cognitive impairment in a large-scale online assessment uncovers a distinct Multiple Sclerosis subtype with selective cognitive impairment. *Nat Commun*. 2025;16(1):1162.
12. Gajewski B, Karlińska I, Stasiótek M. Symbol Digit Modalities Test in progressive multiple sclerosis. *Neurol Neurochir Pol*. 2024;58(3):221-232.
13. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. *Neurology*. 1989;39(2 Pt 1):161-166.
14. Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. *Lancet Neurol*. 2015;14(3):302-317.
15. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. *Lancet Neurol*. 2015;14(2):208-223.
16. Montalban X, Hauser SL, Kappos L, et al. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. *Lancet Neurol*. 2024;23(3):277-295.
17. Feinstein A, Amato MP, Bricchetto G, et al. Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial. *Lancet Neurol*. 2023;22(10):912-924.
18. Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. *Lancet*. 2017;390(10111):2481-2489.

19. Wesnes K. The value of assessing cognitive function in drug development. *Dialogues Clin Neurosci*. 2000;2(3):183-202.
20. Wesnes KA, Edgar C. Norms for healthy adults aged 18-87 years for the Cognitive Drug Research System: An automated set of tests of attention, information processing and memory for use in clinical trials. *J Psychopharmacol*. 2014;28(11):1026-1033.